Eltrombopag
- PDF / 169,515 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 99 Downloads / 139 Views
1 S
Bone marrow fibrosis and lack of efficacy: 6 case reports In a retrospective study of 32 patients who were treated between September 2017 and July 2019, 6 patients [ages and sexes not stated] were described, who developed bone marrow fibrosis (1 patient) or exhibited lack of efficacy (5 patients) during treatment with eltrombopag for post-transplant thrombocytopenia. All six patients, who had undergone transplantation, developed post-transplant thrombocytopenia and started receiving eltrombopag 50 mg/day. Out of 6 patients, one patient developed eltrombopag-related adverse effect including bone marrow fibrosis and remaining 5 patients showed no response to eltrombopag therapy. Five patients, who did not show response to the therapy, died due to CMV infection (1 Patient), encephalitis infection (1 Patient), pulmonary infection and encephalitis infection (1 Patient), and relapse of original malignant disease (2 Patients). Out of 2 patients, who died due to relapse of original malignant disease, one patient had secondary poor graft function and another patient had secondary failure of platelet recovery. The patient with bone marrow fibrosis stopped eltrombopag therapy. Primary poor graft function was noted two patients and secondary poor graft function was also noted in the patient who had pulmonary infection and encephalitis infection. Gao F, et al. Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia. Annals of Hematology 803516061 99: 2679-2687, No. 11, Nov 2020. Available from: URL: http://doi.org/10.1007/s00277-020-04106-2
0114-9954/20/1831-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 21 Nov 2020 No. 1831
Data Loading...
